LEAP THERAPEUTICS nach der KE 2019

https://www.leaptx.com/

LEAP THERAPEUTICS, INC.

6,571,428 Shares of Common Stock

and Warrants to Purchase up to 6,571,428 Shares of Common Stock

https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm

https://www.sec.gov/Archives/edgar/data/1509745/...a18-19040_110q.htm

https://www.sec.gov/Archives/edgar/data/1509745/...a2237643z424b5.htm

Cash and cash equivalents zum Ende Q3 waren 23,249 Mio$

Vorrausschauend haben sie das cash zum Ende Q4 mit 16,3 Mio$ angegeben.

Verbrennen vorraussichtlich um die 7 Mio$ im Q.

Mit der KE sollten sie, gerechnet ab Q1, mit 28,7 Mio cash veranschlagt werden.

As of November 6, 2018 there were 14,703,159 shares of the registrant’s common stock,

Common stock to be outstanding immediately after this offering

21,274,587 shares of common stock (or 22,260,301 shares of common stock if the underwriters exercise their option to purchase additional shares and/or warrants in full).

Die KE mit 6,571,428 Shares of Common Stock and 6,571,428 Warrants

Bei der KE haben sie für jede Aktie mit Warrant 1,75$ bezahlt. Wobei jeder Warrant noch einen Ausübungspreis von $1.95 per share besitzt.#

Ausgehend von 22,26 Mio Aktien und einem Kurs von 1,47, ergibt eine MK von 32,7 Mio bei einem cash von  rund 28 Mio$.

Die Pipeline:     https://www.leaptx.com/our-pipeline

Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities

https://www.ariva.de/news/...s-closing-of-public-offering-and-7393589

20,7% https://investors.leaptx.com/static-files/...0-4b07-be40-47da47c1f23a

6,5% https://investors.leaptx.com/static-files/...5-4477-94eb-3a9925c9e058

17,9% https://investors.leaptx.com/static-files/...7-41c9-a509-877699f68da8

9,6% https://investors.leaptx.com/static-files/...e-47d7-a37d-d7e6f018719e

Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

https://www.ariva.de/news/...nt-at-the-society-of-gynecologic-7455424

 

1,75$ Jetzt ist der Aktienpreis der letzten KE erreicht.

;-)

Absichern! ;-)

OK, jetzt nerve ich nicht weiter !

Perf. seit Threadbeginn:   +57,00%
Mein Ziel ist erreicht! Gewinne lasse ich laufen. Man soll ja nicht zu gierig sein!;-)))

the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer.
https://www.ariva.de/news/...esents-at-society-of-gynecologic-7470993

Poster https://docs.wixstatic.com/ugd/...03e4ba126f3464d9a0d078841bea21b.pdf

Leap Therapeutics Reports Clinical Update and 2018 Financial Results

Leap believes that its current cash and the expected receipt of research and development tax incentives will be sufficient to fund its operating expenses into the second quarter of 2020.

As of March 26, 2019 there were 22,260,301 outstanding shares of the registrant's common stock

https://www.ariva.de/news/...inical-update-and-2018-financial-7501801

https://investors.leaptx.com/node/7376/html

Über die max. Aktienanzahl die von Leap verkauft werden dürfen.

https://investors.leaptx.com/node/7386/html

Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

CAMBRIDGE, Mass., April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2019 Needham & Company 18^th Annual Healthcare Conference, being held in New York City on April 9-10, 2019.

https://investors.leaptx.com/news-releases/...ham-company-18th-annual

https://docs.wixstatic.com/ugd/...a704037d5e3462c8dfe7f075cb867e1.pdf

-2019 finanziert!

We expect that our cash and cash equivalents of $16.3 million at December 31, 2018, together with the net proceeds from the February 2019 Public Offering of $12.1 million and the receipt of $0.8 million of research and development tax incentive payments from the Commonwealth of Australia as a result of the 2018 research and development activities of our Australian subsidiary, HealthCare Pharmaceuticals Pty Ltd, will be sufficient to fund our operating expenses for at least the next 12 months from issuance of the financial statements included in this Annual Report on Form 10-K

DKN-01

Combination with KEYTRUDA®

•Enrollment complete: 52 PD-1/PD-L1 naïve patients

•Mature data Q3 2019•Clinical outcomes in GEJ/Gastric patients

•Enabling biomarkers --DKK1, PD-L1

Monotherapy and Combination with paclitaxel

•78 patients enrolled across 4 treatment arms

•Updated efficacy data Q3 2019

•Enabling biomarkers –activating Wntpathway mutations, DKK1

TRX518

Combination with KEYTRUDA®/OPDIVO

•12 patients enrolled in Keytruda expansion, 20 total expected in Q2 2019

•Efficacy data Q4 2019

https://docs.wixstatic.com/ugd/c343d0_8716992ddbf44ecbaf4474ebc3d8f46a.pdf

https://investors.leaptx.com/node/7426/html

https://investors.leaptx.com/node/7416/html

--22,260,301 and 14,703,159 shares issued and outstanding as of March 31, 2019 and December 31, 2018

Der Anstieg der Aktien ist durch die Feb.2019 KE (Rund 7,5 Mio Aktien zu 1,75$ und 7,5 Mio Warrants mit einem Ausgabepreis von 1,95$)

--Rund 22 Mio$ cash
--Verbrennen ca. 8-9 Mio im Q
--MK 32,5 Mio (21.5.19)
-- Warants
2,758,094         $ 1.75
7,557,142         $ 1.95
investors.leaptx.com/node/7416/html

Company Overview Mai19
docs.wixstatic.com/ugd/...6f10968328346de9817bc80ea16051d.pdf

Pipeline
www.leaptx.com/our-pipeline

DKN-01

Combination with KEYTRUDA®

•Enrollment complete: 52 PD-1/PD-L1 naïve patients

•Mature data Q3 2019•Clinical outcomes in GEJ/Gastric patients

•Enabling biomarkers --DKK1, PD-L1

Monotherapy and Combination with paclitaxel

•78 patients enrolled across 4 treatment arms

•Updated efficacy data Q3 2019

•Enabling biomarkers –activating Wntpathway mutations, DKK1

DKN-01  
clinicaltrials.gov/ct2/...DKN-01&draw=1&rank=4#rowId3

18.3.19 Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer   www.prnewswire.com/news-releases/...ens-cancer-300813624.html




TRX518
clinicaltrials.gov/ct2/...try=&state=&city=&dist=

immuno-oncologynews.com/trx518/
ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3017

4.6.19  EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY,
www.esmo.org/Oncology-News/...active-Target-for-Immunotherapy